Abstract

Allergic rhinitis (AR), a common chronic disease, impairs patients’ quality of life (QoL). This study aimed to determine the effect of perceived stress on disease-related QoL in AR patients. There were 741 patients from eight medical centers of the Allergic Rhinitis Cohort (ARCO) study. Data on sociodemographics, chronic conditions, AR severity, perceived stress level and Rhinoconjunctivitis QoL Questionnaire (RQLQ) results, and laboratory test findings were collected. The relationship between perceived stress and total RQLQ was analyzed using multiple linear regression. Potential confounding variables were adjusted. A high perceived stress level was associated with a high total RQLQ, which reflected worsening disease-related QoL. The high stress level was associated with an increased total RQLQ of 1.210 (95% confidence interval, 0.831–1.589; p < 0.0001) compared with the very low level. In the final model, the multiple regression-adjusted R2 for RQLQ in AR participants was 0.5279, and perceived stress levels contributed 4.08% in additional explanatory power to RQLQ in AR patients. In conclusion, perceived stress is a potentially modifiable risk factor for decreased disease-related QoL in patients with AR, which may be improved with stress management.

Highlights

  • Allergic rhinitis (AR) is one of the most common chronic diseases with a high global burden

  • Perceived stress levels were associated with a high total Rhinoconjunctivitis QoL Questionnaire (RQLQ) score, which reflected poor disease-related quality of life (QoL)

  • We demonstrated that perceived stress was associated with a significant elevation in RQLQ

Read more

Summary

Introduction

Allergic rhinitis (AR) is one of the most common chronic diseases with a high global burden. It is characterized by an IgE-mediated immune reaction to allergens. In a European multicenter study [1], the age- and sex-standardized prevalence of AR in people aged 20 to 44 years ranged from 11.8% to 46.0%. In the International Study of Asthma and Allergy in Childhood (ISAAC) [2], AR prevalence increased from 8.5% in individuals aged 6 to 7 years to 14.6% in those aged 13 to 14 years. Examination Survey [3] reported that the overall prevalence of AR based on laboratory tests was 16.2%. Allergen immunotherapy may be indicated in AR patients who have insufficient symptom control despite medication [4,5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call